Compare JPMorgan Chase & Co (JPM) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Koninklijke Philips NV — how do they compare? JPMorgan Chase & Co trades at $342.5 (market cap $900.78B), while Koninklijke Philips NV trades at $26.57 (market cap $26.19B). The key difference: JPMorgan Chase & Co is far larger — about 34.4× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (3.79%). Which is the better fit depends on your goals.
| JPM | PHG | |
|---|---|---|
Market Cap | $900.78B | $26.19B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $32.91 |
52-Week Low | $282.84 | $24.54 |
Dividend Yield | 1.77% | 3.79% |
Enterprise Value | — | $32.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $339.90, down 0.35% on the day, with strong technical momentum showing bullish moving averages and key support at $339. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst consensus remains positive with a $372.73 price target, though CEO Jamie Dimon's recent warnings highlight economic risks.
JPMorgan presents a compelling investment case with solid fundamentals and Wall Street support, though investors face risks from macroeconomic volatility, cybersecurity threats, and geopolitical tensions. The stock's current valuation below analyst targets suggests potential upside if earnings momentum continues through upcoming quarterly results.
PHG trades at $26.80, down 0.56% with bearish technical signals. The company shows improved fundamentals with net income turning positive to $895M in 2025 after previous losses, though revenue declined slightly to $17.83B. Analyst consensus is mixed with 40.9% buy ratings but technical indicators show selling pressure. Recent developments include FDA clearances for AI-powered medical devices and strategic healthcare partnerships.
PHG presents a turnaround story with profitability recovery but faces execution risks amid competitive pressures. The stock offers value at reasonable valuations (P/E 23.67, P/S 1.29) but requires monitoring of revenue stabilization and AI product adoption. Near-term catalyst includes Q2 2026 earnings with expected EPS of $0.40.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
